Abstract
Virological failure to protease inhibitor (PI)-based antiretroviral regimens is often not explained by the selection of PI resistance mutations. The role of low PI plasma levels in treatment failure was assessed in 30 patients failing nelfinavir-containing triple combinations. Approximately a third of the patients showed sub-therapeutic nelfinavir plasma levels. More than two-thirds of them had no drug resistance mutations, suggesting that insufficient nelfinavir levels contributed to treatment failure.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 442-444 |
| Number of pages | 3 |
| Journal | AIDS |
| Volume | 17 |
| Issue number | 3 |
| DOIs | |
| State | Published - Feb 14 2003 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS